Liquidia Corporation Common Stock
$66.88
-$1.51 (-2.21%)
$66.57Day Range$68.72
Key Statistics
Market Cap
$5.99B
Shares Outstanding
89.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 26, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$68.08
Day High
$68.72
Day Low
$66.57
Volume
3.90M
VWAP
$66.95
Prev Close
$68.39
Transactions
--
Acc. Volume
--
About Liquidia Corporation Common Stock
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
PHARMACEUTICAL PREPARATIONSSIC 2834216 employees419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560919.328.4400IPO Jul 26, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001819576
- Composite FIGI
- BBG001J2P905
- Share Class FIGI
- BBG001V0GFD7
- Ticker Root
- LQDA
- SIC Code
- 2834
About Liquidia Corporation Common Stock (LQDA) Stock
Liquidia Corporation Common Stock (LQDA) closed the 2026-09-18 session at $66.88, down 2.21% versus the previous close (-1.51). The stock opened at $68.08 and traded between $66.57 and $68.72 during that session. Session trading volume was 3.9M shares. The volume-weighted average price (VWAP) is $66.95.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia Corporation Common Stock has a market capitalization of $5.99 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. LQDA is listed on the XNAS exchange. The company employs approximately 216 people. Liquidia Corporation Common Stock is headquartered in MORRISVILLE, NC. The recorded listing date is 2018-07-26.
On this page you can find market LQDA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.